Firehawk Pro™ Coronary Rapamycin Target Eluting Stent System Receives NMPA Approval for Marketing

Shanghai, China, 18 July 2022 – Recently, Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) has received approval from the Chinese National Medical Products Administration (NMPA) to market its Firehawk Pro™ Coronary Rapamycin Target Eluting Stent System (“Firehawk Pro™ Stent”).

Consisting of a balloon-expandable coronary stent, groove-binding single-sided drug coating, and a delivery system, Firehawk Pro™ Stent can be used for symptomatic primary coronary artery lesions. The drug on the stent inhibits the proliferation of smooth muscle cells at the patient's lesion to a certain extent and supports the lesion while reducing restenosis. It can also reduce the occurrence of late stent thrombosis through the application of a biodegradable coating. While retaining the targeted drug release performance of its predecessor, Firehawk® Coronary Rapamycin Targeted Eluting Stent System, the design of the new delivery system optimizes the rapid-exchange structure. The profile of the new product reduces significantly due to the use of a double-layer balloon, fluorinated guidewire lumen and a gradient stiffness outer tube, providing better crossability and pushability for vessel diameter between 2.25 mm and 4.00 mm and lesion length of 36 mm or less. This stent system improves the solutions for more complex lesions.

The approval of Firehawk Pro™ Stent further enriches the product line for cardiovascular interventional treatment. In the future, MicroPort® will continue to invest in product innovation and technology development to bring more high-quality and affordable integrated solutions for patients.

About Shanghai MicroPort Medical (Group) Co., Ltd.

Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicoPort® will continue to steadily promote the target global clinical research program, enrich the cardiovascular interventional therapy product line with the support of accumulated clinical research data, and provide patients with more high-quality and inclusive integrated solutions.